Nuveen LLC Purchases Shares of 95,665 Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Nuveen LLC has acquired a new stake in Amphastar Pharmaceuticals, purchasing 95,665 shares valued at approximately $2.77 million, representing about 0.20% ownership.
• Analysts have mixed ratings for Amphastar, with two ratings as a Buy, three as a Hold, and a consensus target price of $31.60.
• Amphastar's current share price is $30.26, down 0.8%, with a market capitalization of $1.41 billion and a price-to-earnings ratio of 11.33.

Nuveen LLC purchased a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 95,665 shares of the company's stock, valued at approximately $2,773,000. Nuveen LLC owned approximately 0.20% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. Signaturefd LLC lifted its position in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after buying an additional 520 shares in the last quarter. IFP Advisors Inc bought a new stake in Amphastar Pharmaceuticals during the 1st quarter worth about $34,000. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals during the 4th quarter worth about $38,000. GAMMA Investing LLC lifted its position in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after purchasing an additional 348 shares during the period. 65.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AMPH has been the subject of several recent analyst reports. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price for the company in a research note on Tuesday, August 12th. Bank of America raised their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Wells Fargo & Company cut their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Finally, Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday, August 8th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $31.60.

Amphastar Pharmaceuticals Stock Performance

Amphastar Pharmaceuticals stock traded down $1.42 during trading hours on Wednesday, hitting $29.39. The company had a trading volume of 566,956 shares, compared to its average volume of 608,200. The firm has a market cap of $1.37 billion, a PE ratio of 11.01 and a beta of 0.80. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96. The firm has a 50-day moving average of $24.96 and a 200 day moving average of $25.77.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.